{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:45:29Z","timestamp":1793389529812,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0506904"],"award-info":[{"award-number":["2023ZD0506904"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100064"],"award-info":[{"award-number":["82100064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023B03J1291"],"award-info":[{"award-number":["2023B03J1291"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117388","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:26:23Z","timestamp":1759472783000},"page":"117388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P3","title":["A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt\/NF-\u03baB pathway to inhibit activated hepatic stellate cells"],"prefix":"10.1016","volume":"242","author":[{"given":"Wenbin","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Zijian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.bcp.2025.117388_b0005","doi-asserted-by":"crossref","first-page":"20861","DOI":"10.1021\/acsnano.4c02380","article-title":"Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems","volume":"18","author":"Liu","year":"2024","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.bcp.2025.117388_b0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastro Hepat."},{"key":"10.1016\/j.bcp.2025.117388_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.05.016","article-title":"Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents","volume":"121","author":"B\u00f6ttcher","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2025.117388_b0020","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bcp.2025.117388_b0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117388_b0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jhep.2011.07.010","article-title":"A role for autophagy during hepatic stellate cell activation","volume":"55","author":"Thoen","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2025.117388_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104720","article-title":"Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy","volume":"155","author":"Cai","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117388_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2025.117388_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153294","article-title":"Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-\u03b2\/Smad and YAP signaling","volume":"78","author":"Xiang","year":"2020","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.bcp.2025.117388_b0050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3892\/ijmm.2020.4778","article-title":"TGF\u2011\u03b21\u2011induced autophagy activates hepatic stellate cells via the ERK and JNK signaling pathways","volume":"47","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117388_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2018.12.003","article-title":"Liquiritigenin inhibits hepatic fibrogenesis and TGF-\u03b21\/Smad with Hippo\/YAP signal","volume":"62","author":"Lee","year":"2019","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.bcp.2025.117388_b0060","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/HEP.0000000000000319","article-title":"Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-\u03b2\/SMAD signaling","volume":"78","author":"Song","year":"2023","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.bcp.2025.117388_b0065","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0092-8674(02)00703-1","article-title":"Missing pieces in the NF-kappaB puzzle","volume":"109","author":"Ghosh","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117388_b0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117388_b0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-kappaB in the liver\u2013linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117388_b0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","article-title":"Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation","volume":"81","author":"Taru","year":"2024","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117388_b0085","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.02.081","article-title":"Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis","volume":"136","author":"Oakley","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bcp.2025.117388_b0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.510300327","article-title":"Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins","volume":"30","author":"Elsharkawy","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bcp.2025.117388_b0095","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1053\/j.gastro.2007.02.033","article-title":"Gene expression profiles during hepatic stellate cell activation in culture and in vivo","volume":"132","author":"De Minicis","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2025.117388_b0100","first-page":"56","article-title":"Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF-\u03baB pathways","volume":"10","author":"Zhang","year":"2023","journal-title":"Mil. Med. Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117388_b0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3350\/cmh.2022.0068","article-title":"Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-\u03baB signaling pathways","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117388_b0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12072-019-09997-6","article-title":"TAF and TDF attenuate liver fibrosis through NS5ATP9, TGF\u03b21\/Smad3, and NF-\u03baB\/NLRP3 inflammasome signaling pathways","volume":"14","author":"Zhao","year":"2020","journal-title":"Hepatol. Int."},{"issue":"2","key":"10.1016\/j.bcp.2025.117388_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.etp.2005.08.003","article-title":"L-Arginine-NO-cGMP signaling following acute liver injury in the rat","volume":"57","author":"Minin","year":"2005","journal-title":"Exp. Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117388_b0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3748\/wjg.14.236","article-title":"Elevated nitric oxide and 3',5' cyclic guanosine monophosphate levels in patients with alcoholic cirrhosis","volume":"14","author":"Siqueira","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117388_b0125","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00657.2013","article-title":"Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis","volume":"306","author":"Cui","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117388_b0130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/ki.2013.219","article-title":"The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis","volume":"84","author":"Schinner","year":"2013","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.bcp.2025.117388_b0135","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/db10-0760","article-title":"Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia","volume":"60","author":"Lutz","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2025.117388_b0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.metabol.2018.09.001","article-title":"cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation","volume":"88","author":"Franko","year":"2018","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.bcp.2025.117388_b0145","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3390\/cancers12123748","article-title":"Dual pharmacological targeting of HDACs and PDE5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis","volume":"12","author":"Claveria-Cabello","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.bcp.2025.117388_b0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications","volume":"1","author":"Rotella","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bcp.2025.117388_b0155","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/2050640620944140","article-title":"Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats","volume":"8","author":"Brusilovskaya","year":"2020","journal-title":"United European Gastroenterol. J."},{"issue":"12","key":"10.1016\/j.bcp.2025.117388_b0160","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1139\/cjpp-2018-0338","article-title":"The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats","volume":"96","author":"Mansour","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117388_b0165","unstructured":"Wan YQ, Ke HM, Chen G, Wang HC, Zhu XH, Zheng ZC. Pyrazole pyrimidine ketone derivatives and their pharmaceutically acceptable salts: preparation methods and applications. patent: CN102020645A., 2011-04-20."},{"key":"10.1016\/j.bcp.2025.117388_b0170","unstructured":"Allan Zhao ZJ, Mu YP, Li FH, Zhao ZG, Zhu HD. A potassium salt crystal form B of a type 5 phosphodiesterase inhibitor and its preparation method and application. patent: CN201910505948.5, 2022-03-01."},{"key":"10.1016\/j.bcp.2025.117388_b0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.fct.2018.07.027","article-title":"Hepatoprotective effects of diosmin and\/or sildenafil against cholestatic liver cirrhosis: the role of Keap-1\/Nrf-2 and P38-MAPK\/NF-\u03baB\/iNOS signaling pathway","volume":"120","author":"Ali","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117388_b0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis: mechanistic concepts and therapeutic perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells-Basel"},{"issue":"14","key":"10.1016\/j.bcp.2025.117388_b0185","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"Jama-J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.bcp.2025.117388_b0190","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2174\/0929867327666200923151924","article-title":"Repurposing of the PDE5 inhibitor sildenafil for the treatment of persistent pulmonary hypertension in neonates","volume":"28","author":"Poitras","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117388_b0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/med.20053","article-title":"Phosphodiesterase 5 (PDE5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6","volume":"26","author":"Pissarnitski","year":"2006","journal-title":"Med. Res. Rev."},{"issue":"17","key":"10.1016\/j.bcp.2025.117388_b0200","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/ijms21176223","article-title":"Phosphodiesterases in the liver as potential therapeutic targets of cirrhotic portal hypertension","volume":"21","author":"Kreisel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117388_b0205","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6970407","article-title":"PPAR\u03b3 antagonizes hypoxia-induced activation of hepatic stellate cell through cross mediating PI3K\/AKT and cGMP\/PKG signaling","volume":"2018","author":"Zhang","year":"2018","journal-title":"PPAR Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117388_b0210","article-title":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"Jhep Rep."},{"issue":"11","key":"10.1016\/j.bcp.2025.117388_b0215","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/ndt\/gfn319","article-title":"PDE-5 inhibition impedes TSP-1 expression, TGF-\u03b2 activation and matrix accumulation in experimental glomerulonephritis","volume":"23","author":"Hohenstein","year":"2008","journal-title":"Nephrol. Dial Transpl."},{"issue":"4","key":"10.1016\/j.bcp.2025.117388_b0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-007-9039-5","article-title":"Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of Ikappabalpha degradation in liver stellate cells","volume":"24","author":"Hern\u00e1ndez","year":"2008","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117388_b0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:27:44Z","timestamp":1762097264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"alternative-id":["S0006295225006537"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117388","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt\/NF-\u03baB pathway to inhibit activated hepatic stellate cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117388"}}